Abeona Therapeutics updated its investor presentation for use at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Investors receive the materials Abeona expects to use at the conference, including the presentation dated for the event and identified under Regulation FD.
Key Highlights
- Abeona Therapeutics’ disclosure is made under Regulation FD.
- Chief Financial Officer Joseph Vazzano signed on behalf of Abeona Therapeutics on September 15, 2026.
- Abeona Therapeutics prepared an updated presentation for the Wainwright Conference.
The materials are intended for use either in full or in part during the event.
Updated Presentation Prepared for Wainwright Conference
Abeona Therapeutics is furnishing the materials under Regulation FD. Joseph Vazzano, Abeona Therapeutics’ chief financial officer, signed the disclosure on behalf of the company on September 15, 2026. The disclosure also identifies Abeona Therapeutics Inc. (NASDAQ: ABEO) as the registrant and cites the Securities Exchange Act of 1934 in its signature language.
FAQs
Q: Which investor event is connected with ABEO’s updated presentation?
A: The updated presentation is prepared for the Wainwright Conference. Abeona Therapeutics furnished the materials under Regulation FD for use in full or in part during the event.
Q: Who signed Abeona Therapeutics’ disclosure?
A: Joseph Vazzano signed on behalf of Abeona Therapeutics. He is identified as the company’s chief financial officer, and the signature date is September 15, 2026.
Q: What event was the updated presentation prepared for?
A: The updated presentation was prepared for the Wainwright Conference.
Q: When did Joseph Vazzano sign the disclosure?
A: Joseph Vazzano signed the disclosure on September 15, 2026. He signed on behalf of Abeona Therapeutics as the company’s chief financial officer.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.